Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 23;14(15):5206.
doi: 10.3390/jcm14155206.

Ultrasound Pattern of Indeterminate Thyroid Nodules with Prevalence of Oncocytes

Affiliations

Ultrasound Pattern of Indeterminate Thyroid Nodules with Prevalence of Oncocytes

Sium Wolde Sellasie et al. J Clin Med. .

Abstract

Objectives: Oncocyte-rich indeterminate thyroid nodules (O-ITNs) present diagnostic and management challenges due to overlapping features between benign and malignant lesions and differing cytological classifications. This study aimed primarily to assess the ultrasound (US) characteristics and US-based risk of O-ITNs using the American College of Radiology Thyroid Imaging Reporting And Data Systems (ACR TI-RADS). A secondary objective was to compare the Bethesda System for Reporting Thyroid Cytopathology (BSRTC) and Italian Consensus for the Classification and Reporting of Thyroid Cytology (ICCRTC) cytological systems regarding classification and clinical management implications for O-ITNs. Methods: A retrospective study was conducted on 177 ITNs (TIR3A and TIR3B) evaluated between June 2023 and December 2024 at CTO-Alesini, Rome (Italy). Nodules were assessed with US, cytology, and histology. Oncocyte predominance was defined as >70% oncocytes on fine-needle aspiration (FNA). US features were analyzed according to ACR TI-RADS. Nodules were reclassified by BSRTC, and potential differences in clinical case management (CCM) were analyzed. Results: O-ITNs comprised 47.5% of the sample. Compared to non-O-ITNs, O-ITNs were larger and more frequently showed low-risk US features, including a higher prevalence of ACR TI-RADS 3 nodules. However, no progressive increase in the risk of malignancy (ROM) was observed across ACR TI-RADS classes within O-ITNs. Histological malignancy was identified in 47.1% of O-ITNs, a lower proportion compared to non-O-ITNs, though the difference was not statistically significant. Classification discordance with potential management impact was lower in O-ITNs (20.2%) than in non-O-ITNs (38.7%). Conclusions: O-ITNs typically exhibit benign-appearing US features and lower classification discordance between BSRTC and ICCRTC, yet US risk stratification fails to differentiate malignancy risk within O-ITNs. A tailored approach integrating cytology and cautious US interpretation is essential for optimal O-ITN management.

Keywords: ACR TI-RADS; cytology; indeterminate thyroid nodules; oncocytes; ultrasound.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
ACR TI-RADS distribution in ITNs according to ICCRTC.
Figure 2
Figure 2
US presentation of O-ITN, with anteroposterior (D1), lateral (D2), and longitudinal (D3)diameters, classified as ACR TI-RADS 3, with a TIR3A cytologic report and a proven histology of oncocytic adenoma.

Similar articles

References

    1. Wong K.S., Angell T.E., Barletta J.A., Krane J.F. Hürthle cell lesions of the thyroid: Progress made and challenges remaining. Cancer Cytopathol. 2021;129:347–362. doi: 10.1002/cncy.22375. - DOI - PubMed
    1. Máximo V., Soares P., Lima J., Cameselle-Teijeiro J., Sobrinho-Simões M. Mitochondrial DNA Somatic Mutations (Point Mutations and Large Deletions) and Mitochondrial DNA Variants in Human Thyroid Pathology. Am. J. Pathol. 2002;160:1857–1865. doi: 10.1016/S0002-9440(10)61132-7. - DOI - PMC - PubMed
    1. Nardi F., Basolo F., Crescenzi A., Fadda G., Frasoldati A., Orlandi F., Palombini L., Papini E., Zini M., Pontecorvi A., et al. Italian consensus for the classification and reporting of thyroid cytology. J. Endocrinol. Investig. 2014;37:593–599. doi: 10.1007/s40618-014-0062-0. - DOI - PubMed
    1. Ali S.Z., Baloch Z.W., Cochand-Priollet B., Schmitt F.C., Vielh P., VanderLaan P.A. The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2023;33:1039–1044. doi: 10.1089/thy.2023.0141. - DOI - PubMed
    1. Tessler F.N., Middleton W.D., Grant E.G., Hoang J.K., Berland L.L., Teefey S.A., Cronan J.J., Beland M.D., Desser T.S., Frates M.C., et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J. Am. Coll. Radiol. 2017;14:587–595. doi: 10.1016/j.jacr.2017.01.046. - DOI - PubMed

LinkOut - more resources